TY  - JOUR
AU  - Vidal, J
AU  - Bellosillo, B
AU  - Santos Vivas, C
AU  - Garcia-Alfonso, P
AU  - Carrato, A
AU  - Cano, M T
AU  - Garcia-Carbonero, R
AU  - Elez, E
AU  - Losa, F
AU  - Massuti, B
AU  - Valladares-Ayerbes, M
AU  - Vieitez, J M
AU  - Manzano, J L
AU  - Azuara, D
AU  - Gallego, J
AU  - Pairet, S
AU  - Capella, G
AU  - Salazar, R
AU  - Tabernero, J
AU  - Aranda, E
AU  - Montagut, C
PY  - 2019
DO  - 10.1093/annonc/mdz005
UR  - http://hdl.handle.net/10668/13472
T2  - Annals of oncology : official journal of the European Society for Medical Oncology
AB  - Extended RAS analysis is mandatory in metastatic colorectal cancer (mCRC) patients. The optimal threshold of RAS mutated subclones to identify patients most likely to benefit from antiepidermal growth factor receptor (EGFR) therapy is controversial....
LA  - en
PB  - Elsevier
KW  - NGS
KW  - RAS mutations
KW  - Anti-EGFR
KW  - Colorectal cancer
KW  - Mutant allele fraction
KW  - Quadruple wild-type
KW  - Adult
KW  - Antineoplastic combined chemotherapy protocols
KW  - Cetuximab
KW  - Class I phosphatidylinositol 3-kinases
KW  - Colorectal neoplasms
KW  - DNA mutational analysis
KW  - Disease-free survival
KW  - ErbB receptors
KW  - Female
KW  - GTP phosphohydrolases
KW  - Germany
KW  - High-throughput nucleotide sequencing
KW  - Humans
KW  - Male
KW  - Membrane proteins
KW  - Middle aged
KW  - Mutation
KW  - Neoplasm metastasis
KW  - Protein kinase inhibitors
KW  - Proto-oncogene proteins B-raf
KW  - Proto-oncogene proteins p21(ras)
KW  - Treatment outcome
TI  - Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
TY  - research article
VL  - 30
ER  -